Alligator Bioscience Logo
SE0024173637
A41BED

Alligator Bioscience

Cargando cotizaciones...

Previsión

No hay datos de analistas disponibles para esta empresa.

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • Alligator Bioscience stops Mitazalimab development, stock plunges 74%

    Alligator Bioscience’s board has halted further independent development of the CD40 antibody Mitazalimab due to the rapidly changing treatment landscape in pancreatic cancer and intends to out-license or sell the drug. Resources will be redirected to HLX22 (anti-HER2), which is being developed externally by Shanghai Henlius Biotech; Alligator will receive revenue participation for this without development expense. The company also announced a rights issue of around SEK 125.6 million and a bridge financing; cash of SEK 33 million will only last until mid-Q3 2026. The combination of the project halt, a heavily dilutive capital measure and strained liquidity triggered the sharp share price decline. » Más en de.investing.com


  • Alligator Bioscience cuts costs sharply and plans phase‑III start for mitazalimab

    Alligator Bioscience reports significant cost reductions in Q1 2026 (annualized operating costs cut from 300 to 100 million SEK; Q1 costs 17 million SEK) and reports cash of 33 million SEK. Lead candidate mitazalimab showed a 30‑month survival rate of 20% in Phase II, and the company is preparing to start a Phase‑III trial in Q4 2026; a regulatory submission is expected in Q2 2026. Because cash is only expected to last until mid‑Q3 2026, Alligator is actively exploring financing options. The stock rose 4.69% following the results. » Más en de.investing.com

Datos financieros de la empresa

En el último trimestre, Alligator Bioscience tuvo unos ingresos de 20,9 mil € y un beneficio neto de -1,47 M €
(EUR) septiembre de 2026
YoY
Ingresos 20,9 mil 50,63 %
Beneficio bruto -1,31 M -
Beneficio neto -1,47 M 32,53 %
EBITDA -1,72 M 155,43 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
41,96 mil €
Número de acciones
53,09 M
Máximo/mínimo de 52 semanas
0,11 € - 0,000781 €
Dividendos No
Beta
1,17
Ratio P/E
-0,01
Ratio PEG
0,00
Ratio P/B
0,24
Ratio P/S
1,65

Perfil de la empresa

Nombre
Alligator Bioscience
CEO
Søren Bregenholt
Empleados 11
🍪

Parqet  usa cookies. Más información